Biotech News

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis

Organogenesis (ORGO)Organogenesis2026-07-06 20:05 ESTFDA / regulatory

PDUFA Target Action Date Set for April 24, 2027 CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced

Organogenesis

Regenerative Medicine Organogenesis develops and manufactures regenerative-medicine products used to support healing in difficult wounds and surgical procedures. Advanced Wound Care The company's wound-care portfolio includes cellular and tissue-based products, placental-derived products and other biologic matrices used in chronic and...

Recent company news

ORGOOrganogenesis2026-08-06 20:05 EST

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

ORGOOrganogenesis2026-07-27 20:05 EST

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

ORGOOrganogenesis2026-07-09 11:30 EST

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026

ORGOOrganogenesis2026-07-06 20:05 EST